Measuring the impact of collaborations between advocacy and industry is a best practice, yet not consistently employed. Collaborations require time, financial and employee resources therefore should be carefully thought about as investments in drug development programs. Each investment should ideally lead to an optimization that can be measured and reported back to the participants so that every individual understands what happened as a result of the investment of their time and other resources.
It is recommended that with each engagement, collaborators establish at the outset, a set of objectives and outcomes expected. Metrics should be linked to these objectives to help determine if the impact was as expected. If the outcomes were less than expected, having quantitative measures in place will help groups identify how to better refine future engagements.
Some examples are:
Risk-adjusted financial models can assess the impact of patient engagement. A combination of empirical data and subjective parameter estimates shows that engagement activities with the potential to avoid protocol amendments and/or improve enrollment, adherence, and retention may add considerable financial value. This approach can help sponsors assess patient engagement investment decisions.
Reference:
Disclaimer | Non-Discrimination | Privacy | Terms for Creating and Maintaining Sites